Ready-to-use Therapeutic Food (RUTF) Market Size, Share, and Growth Forecast, 2026 – 2033

The global ready-to-use therapeutic food market size is likely to be valued at US$824.6 million in 2026 and is estimated to reach US$1,215.5 million by 2033, growing at a CAGR of 5.7% during the forecast period 2026−2033, driven by persistent childhood severe wasting, expansion of community-based treatment, stronger nutrition policies, localization of production, and wider health-system integration. Demographic pressure remains a core demand factor, with severe wasting affecting millions of children under five across regions exposed to food insecurity, conflict, disease outbreaks, and climate-related disruption.

Driver - Persistent Severe Wasting and Treatment Demand

Severe wasting remains a structural driver as children affected by acute malnutrition require rapid nutritional intervention. United Nations International Children's Emergency Fund (UNICEF) reported that 12.2 million children under five suffered from severe wasting in 2024. The burden is concentrated across regions affected by food insecurity, infectious disease, displacement, and fragile health systems. These conditions create recurring requirements for community-based therapeutic nutrition programs.

Public funding can convert identified nutritional need into procurement demand. In August 2025, the US Department of State announced a US$93 million grant to UNICEF to deliver RUTF to nearly 1 million acutely malnourished children across 13 countries. The programme also required the RUTF supplied under the grant to be manufactured in the U.S., connecting public financing with domestic production capacity and international humanitarian distribution.

Expansion of Community-Based Management

Community-based treatment is increasing the practical reach of RUTF because uncomplicated severe wasting can be managed outside hospitals when children receive appropriate clinical monitoring. World Health Organization (WHO) guidance supports outpatient use of RUTF for children aged 6–59 months with severe wasting and/or nutritional edema, creating a standardized clinical pathway for national programs.

Infrastructure development strengthens this model through trained health workers, community screening, decentralized dispensing, stock monitoring, and referral systems. UNICEF reported that more than 255.3 million children under five were screened for wasting in 54 countries during 2025, while 9 million children with severe wasting were admitted for life-saving treatment. The expansion of screening and treatment networks supports recurring procurement and distribution requirements.

Restraint - Funding Volatility and Uneven Procurement

Funding volatility can restrict scalability even when production capacity exists. UNICEF reported that funded RUTF demand remained below available production capacity, creating a mismatch between installed capacity and financed treatment requirements. Suppliers therefore face difficulty maintaining efficient utilization when procurement volumes fluctuate, while manufacturers must preserve quality systems and production readiness despite uncertain order schedules.

Reduced utilization can pressure operating margins because fixed manufacturing costs, quality assurance requirements, workforce expenses, and equipment maintenance continue during periods of lower output. Smaller local manufacturers can face greater exposure because limited production volumes reduce opportunities to capture economies of scale and negotiate lower ingredient and packaging costs.

Input Cost and Logistics Exposure

RUTF production depends on ingredients such as peanuts, milk powder, oil, sugar, vitamins, minerals, and packaging materials. Changes in agricultural availability, commodity pricing, transportation costs, and import conditions can increase production expenses. UNICEF reported that RUTF weighted average prices increased during 2022–2023 following higher input and logistics costs.

Supply interruptions can reduce manufacturing predictability and increase inventory requirements. Manufacturers serving emergency programs must maintain quality and delivery reliability despite volatile logistics conditions. Higher safety-stock requirements tie up working capital, while international transportation can increase landed costs and reduce the scalability advantage of suppliers located far from major treatment programs.

Opportunity - Expansion through Local RUTF Manufacturing

Local and regional manufacturing provides a direct expansion pathway as production closer to treatment programs can shorten delivery routes, reduce transportation exposure, and improve supply continuity. UNICEF reported that more than half of procured RUTF comes from low- and lower-middle-income countries, while the supplier base expanded to more than 20 manufacturers across Africa, the Americas, Asia, and Europe.

Manufacturers can capture this opportunity through modular production facilities, regional procurement hubs, local agricultural sourcing, and quality systems aligned with Codex requirements. The approach can also strengthen domestic value chains by connecting RUTF production with farmers supplying peanuts, pulses, grains, oils, and other approved ingredients. UNICEF identifies localization as a mechanism for improving supply security and reducing transportation-related environmental impacts.

Alternative Formulations and Ingredient Innovation

Alternative formulations create a pathway to improve cost efficiency, resilience, acceptability, and environmental performance. UNICEF technical specifications permit development of innovative RUTF formulations when nutritional composition, safety, and scientific evidence requirements are satisfied. Soybeans and chickpeas are being assessed as alternatives to peanuts, creating opportunities for suppliers located in regions with strong pulse production.

Companies can develop locally adapted products by combining validated nutritional formulations with regional ingredients and consumer acceptability considerations. Cambodia provides a relevant example through locally produced fish-based RUTF developed with UNICEF and national partners. Local ingredients reduced production costs and supported treatment expansion through health facilities. Such models can support product diversification while maintaining regulatory compliance.

Product Type Insights

RUTF paste is expected to lead the ready-to-use therapeutic food market, accounting for around 72% of revenue in 2026. Its established clinical use, shelf stability, and compatibility with community-based treatment support broad procurement. UNICEF describes RUTF as a nutrient-dense paste supplied in single-use sachets. Standardized manufacturing and extensive procurement experience reinforce adoption across humanitarian and health-system programs.

RUTF biscuits are likely to represent the fastest-growing segment, propelled by portability, convenient administration, and product-format diversification. WHO recognizes compressed biscuits or bars as RUTF formats suitable for severe wasting treatment. For example, BP-100 represents a biscuit-based RUTF option. Product diversification can support programs requiring easier handling, transportation, and administration while maintaining nutritional requirements established under applicable standards.

Application Insights

United Nations Agencies are likely to be the leading segment with a projected 68% of the ready-to-use therapeutic food market share in 2026 due to large-scale procurement, humanitarian response requirements, and centralized purchasing. UNICEF procures approximately 80% of global RUTF supply, creating substantial institutional demand. UNICEF delivered large volumes of RUTF through international nutrition programs, demonstrating the scale of agency-led procurement.

NGOs are anticipated to be the fastest-growing segment, fueled by community-based nutrition programs, emergency response activities, and decentralized treatment delivery. NGOs frequently support screening, referral, health-worker training, and last-mile distribution in areas affected by displacement or weak infrastructure. For example, community-based treatment programs integrate RUTF distribution with local health services, expanding access beyond centralized facilities.

North America Ready-to-Use Therapeutic Food Market Trends

North America is forecast to be the fastest-growing regional market, stimulated by humanitarian financing, domestic RUTF production, and international procurement programs. Institutional procurement supports demand. US-based production strengthens supply capacity. Public funding can expand international RUTF distribution and strengthen regional supply infrastructure.

U.S. Ready-to-use Therapeutic Food Market Insights

The U.S. is projected to represent around 83% of the North America market in 2026, supported by humanitarian financing, domestic production, and institutional procurement. Established manufacturing capabilities strengthen supply availability. International nutrition programs support demand for RUTF products. Regulatory compliance supports institutional procurement. Expanding production capacity can improve supply resilience and strengthen the country’s role in global therapeutic nutrition programs.

Canada Ready-to-use Therapeutic Food Market Insights

Canada is expected to represent around 17% of the North America market in 2026, supported by international nutrition financing and humanitarian programs. Community-based treatment strengthens RUTF access. Development partnerships support procurement and distribution. Continued nutrition initiatives can improve delivery infrastructure. Institutional programs remain an important demand channel for therapeutic nutrition products across international markets.

Europe Ready-to-use Therapeutic Food Market Trends

Europe is expected to account for around 18% of revenue in 2026, supported by established manufacturing capabilities, technical expertise, and international procurement. European suppliers participate in global procurement programs. Product quality standards support institutional purchasing. Alternative ingredients and efficient manufacturing are also gaining attention.

France Ready-to-use Therapeutic Food Market Insights

France is projected to represent around 34% of the Europe market in 2026, supported by established manufacturing capabilities and international procurement. Nutriset remains an important supplier. French manufacturers benefit from established technical expertise and established distribution networks for humanitarian nutrition programs. Product innovation can support formulation development. Established production capabilities strengthen France position in international therapeutic nutrition programs.

U.K. Ready-to-use Therapeutic Food Market Insights

The U.K. is expected to represent around 22% of the Europe market in 2026, supported by humanitarian financing and international nutrition programs. Development initiatives support RUTF procurement. Community-based treatment can improve product access. Institutional demand remains important. Continued funding can strengthen distribution networks. Partnerships with international organizations can support wider therapeutic nutrition coverage.

Asia Pacific Ready-to-use Therapeutic Food Market Trends

Asia Pacific is anticipated to be the leading region, accounting for around 38% of the global revenue in 2026, driven by a high burden of severe wasting and expanding treatment infrastructure. Local manufacturing is strengthening supply resilience. Alternative ingredients support formulation development. Community-based treatment expansion is improving RUTF availability across underserved populations.

China Ready-to-use Therapeutic Food Market Insights

China is expected to represent around 24% of the Asia Pacific market in 2026, supported by large-scale nutrition programs, established food-processing capabilities, and expanding healthcare infrastructure. Domestic production can improve supply availability. Research into specialized nutritional foods supports product development. Strong manufacturing capacity can strengthen regional supply resilience and improve distribution across underserved populations.

India Ready-to-use Therapeutic Food Market Insights

India is projected to represent around 32% of the Asia Pacific market in 2026, supported by domestic manufacturing and expanding nutrition infrastructure. Indian suppliers participate in UNICEF procurement. Local manufacturing can reduce transportation exposure and improve supply continuity for regional treatment programs. Growing healthcare access can support wider distribution. Product development using locally available ingredients can strengthen supply resilience.

The global ready-to-use therapeutic food market is moderately fragmented, with procurement distributed across international and local manufacturers rather than controlled by a single producer. UNICEF reported 23 manufacturers in its 2025 supplier base, while long-term arrangements covered 21 manufacturers through December 2027. Key participants include Nutriset, Edesia, Hilina Enriched Foods, INSTA Products, and GC Rieber Compact.

The competitive structure is shaped by quality compliance, production reliability, geographic proximity, price competitiveness, and eligibility for institutional procurement. Local manufacturers gain advantages from shorter supply routes and lower logistics exposure, while established producers benefit from technical expertise and procurement experience. UNICEF contract awards demonstrate participation from suppliers across Africa, Asia, Europe, the Americas, and other regions.

Key Industry Developments:

• In September 2025, Ghana Health Services, the Eleanor Crook Foundation, and the Clinton Health Access Initiative launched a US$2.15 million partnership to expand RUTF access and achieve 90% national treatment coverage for children with severe wasting.
• In March 2025, the Nutrition for Growth Summit in Paris mobilized US$27.55 billion in global nutrition commitments, reinforcing international efforts to address malnutrition and strengthen nutrition programs.